Search Result: Parkinsons disease
…John Paul Leach, Consultant Neurologist, Southern General Hospital, Glasgow. At the dinner proceeds from the registration fees for the meeting were donated to Parkinson’s UK and Cure Parkinsons by Mr…
Content Section:
Conference Reports
Abstract Polyneuropathies encompass a number of diseases of the peripheral nerves. Causes vary, and some types of polyneuropathy have a chronic disease course, and some have acute onset. Polyneuropathies, such…
Content Section:
Articles
…disease and delay in starting disease modifying treatments can have long-term consequences, the steering committee has recommended that CIS patients with visible abnormalities on MRI scans should receive disease modifying…
Content Section:
News Posts
…FDA-authorised in vitro diagnostic test in the U.S. to aid in the assessment of Alzheimer’s disease and other causes of cognitive decline. Alzheimer’s disease is a leading cause of disability…
Content Section:
News Posts
…to prospectively identify risk indicators of Parkinson’s disease. Mov Disord 2017;32(2):219-226. Hu XW, Qin SM, Li D, Hu LF, Liu CF. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson’s disease: a…
Content Section:
Conference Reports
…of Disease And Relapse – Alzheimer’s Disease). “RADAR-AD’s tailored combination of devices and smartphone applications will act as a powerful new tool in personalised medicine by offering the right treatments…
Content Section:
Conference Reports
…with Parkinson’s disease: the new kids on the block! Expert Rev Neurother 2019;19(2):145-157. Bloem BR, de Vries NM, Ebersbach G. Nonpharmacological treatments for patients with Parkinson’s disease. Mov Disord 2015;30(11):1504-1520….
Content Section:
Conference Reports
…not specific for MS, and has also been demonstrated in Alzheimer’s disease and Parkinson’s disease.13,14 MicroRNAs Micro RNAs (miRNA) are short non-coding RNAs with an important role in post-transcriptional gene…
Content Section:
Articles
Abstract The existence of antibodies to myelin oligodendrocyte glycoprotein (MOG) in some patients with CNS demyelinating disease has been recognised for 30 years, but their clinical utility as biomarkers, and…
Content Section:
Articles